The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

Meeting, held April 24–28 in Honolulu, reveals that young children with chronic conditions are more likely to be hospitalized ...

Young children with chronic conditions are more likely to be hospitalized for respiratory syncytial virus (RSV) than healthy children, according to a new study.

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...

After decades of fits and starts, scientists finally got the world’s first vaccines against respiratory syncytial virus ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older ...